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The article of Felsher and Wender entitled “Picolog, 
a synthetically-available bryostatin analog, inhibits growth 
of MYC-induced lymphoma in vivo” represents a very 
important key step enroute to the clinical exploration 
of members of this natural product class [1]. Although 
bryostatin  1  entered  clinical  trials,  the  difficulty  in 
securing  sufficient  amounts  of  material  from  natural 
sources to ultimately support its clinical use, even with 
its extraordinary potency, led to their discontinuation in 
anticipation of synthetic replacements on the horizon 
[2]. The candidate replacements in this study have come 
from the Wender laboratory, using cutting-edge synthetic 
chemistry to prepare well-conceived designed analogs 
used to explore the structure-function properties and 
mechanism(s) of action of molecules in the class. In 
these efforts, simplified and synthetically more accessible 
candidate drugs have emerged from a >20 year program 
that express more potent and/or altered selectivity for the 
identified biological targets of the natural products [3-5]. 
One of these, the exceptionally potent “picolog”, has now 
been examined in vivo in collaboration with Felsher [6-7], 
providing efficacious anti-neoplastic activity in a clinically 
relevant animal model and compelling data is presented 
that accessible replacements for bryostatin 1 are on the 
way. 
Thus, the study presents the successful results of the 
first examination of a bryostatin analog in an animal model 
indicating that it is both efficacious and well tolerated. The 
work utilized a conditional model of aggressive, MYC-
induced T cell lymphoma relevant to clinical applications 
of bryostatin 1 and provides a valuable pharmacological 
tool for studying such oncogene induced malignancies 
going forward. Additionally, the studies showed that 
picolog, like bryostatin 1, induces apoptosis and operates 
by a mechanism involving PKC activation. Here, the 
authors utilized a novel nano-immuno assay (NIA) that 
allowed them to precisely quantify markers of PKC 
pathway activation in vivo in real time [8-9]. They found 
that two distinct phosphorylated forms of MEK2 in the 
PKC pathway were induced by picolog treatment. With 
these advances, it will be exciting to see how a series of 
bryostatin analogs performs in such in vivo models and 
how this correlates with novel in vivo biomarkers of their 
anticipated mechanisms of action.
Although the present study has focused on oncology, 
bryostatin has also emerged as an exciting lead for 
treatment of Alzheimer’s disease, and for purging latent 
reservoir stores of HIV that are challenging to access in 
the treatment of AIDS. As such, the present demonstration 
of  the  well  tolerated  in  vivo  activity  of  a  simplified 
bryostatin indicates that they, or the appropriate analog 
subset, may be especially useful in the treatment of other 
human diseases going forward. At the very least, they will 
help identify new mechanisms of action relevant to these 
diseases and define the pharmacological characteristics 
candidate drugs should embody. 
Beyond this, the work is especially significant on 
several levels. First, by combining the power of state-
of-the-art synthetic chemistry, fundamental chemical 
and structural design principles, modern biology and 
pharmacology, and innovative technology, new candidate 
drugs have been created that will not only likely find their 
way into the clinic, but have or will define new targets and 
mechanisms of action by which human disease may be 
treated. Second, and more subtle, the work going forward 
will undoubtedly define which subset of the constellation 
of biological properties of bryostatin are responsible for 
the productive activity useful for treating human disease 
and identify which bryostatin structural features convey 
or potentiate these properties. These latter studies provide 
opportunities to improve on Nature’s design, providing 
drugs that are not only more accessible, but are also more 
tailored for an intended human use.
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